Condition
    Moderate Evidence
    Effectiveness 2/5

    Omega-3 Fatty Acids for Non-Alcoholic Steatohepatitis

    Useful for the lipid and steatosis component of fatty liver disease, without evidence of histological resolution.

    Overview

    Useful for the lipid and steatosis component of fatty liver disease, without evidence of histological resolution.

    Verdict

    Mixed evidence

    Omega-3 reliably lowers liver fat and triglycerides but has not been shown to resolve inflammation or improve fibrosis.

    How It Works

    EPA and DHA suppress hepatic de novo lipogenesis via SREBP-1c downregulation and increase fatty acid oxidation through PPAR-alpha activation, reducing triglyceride accumulation in hepatocytes. They also generate specialised pro-resolving mediators with anti-inflammatory activity, though this has not translated into histological endpoints.

    Dosing & Protocol

    Typical dose

    Recommended dose
    2-4 g daily of combined EPA and DHA, taken with food
    Expected timeframe
    Liver fat and triglyceride reductions over 3-6 months

    Protocol

    form
    Triglyceride-form fish oil
    duration
    6-12 months with serial enzymes and fibrosis assessment
    co factor
    Take with dietary fat. Evidence is mixed and the distinction from simple fatty liver matters: omega-3 lowers hepatic fat and triglycerides, but randomised trials including WELCOME did not show improvement in histological inflammation or fibrosis, which are what define NASH.
    titration
    Increase towards 2000-4000 mg/day over a month; NASH trials used 1.8-4 g/day
    starting dose
    1000 mg combined EPA+DHA daily with a meal, with the hepatology team informed

    Evidence

    What the studies say

    The WELCOME trial gave 4 g daily of DHA-rich omega-3 for 15-18 months and found a significant reduction in liver fat measured by magnetic resonance spectroscopy, but no improvement in fibrosis. The EPE-A trial with ethyl-eicosapentaenoic acid failed its histological endpoints. Meta-analyses consistently show reductions in hepatic fat and serum triglycerides, with inconsistent effects on ALT and no reliable effect on ballooning, inflammation or fibrosis. Interpretation is straightforward: omega-3 addresses steatosis and the atherogenic lipid profile that accompanies it, which matters given that cardiovascular disease is the leading cause of death in this population, but it is not a treatment for steatohepatitis itself.

    Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

    Score: 6/10
    2024
    meta_analysis

    Aziz T, Niraj MK, Kumar S +1 more

    Omega-3 supplementation significantly decreased alanine aminotransferase (ALT) (mean difference = -2.12, 95% confidence interval (CI) = -3.36, -0.87) and aspartate aminotransferase (AST) (mean difference = -1.50, 95% CI = -2.59, -0.42).

    View source

    Safety

    Caveats

    High doses may increase bleeding risk with anticoagulants and have been associated with atrial fibrillation in cardiovascular trials. Prescription-grade purity matters at these doses.

    Less likely to help if

    People with predominantly inflammatory or fibrotic disease rather than high liver fat and triglycerides.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.